Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 18/20 | 0.59 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034347 | 0.88 | CCR4 (0.61) | CCR4 | |
| SCHEMBL21048001 | 0.84 | EDNRA (0.58) | CCR4PTGES2EDNRA | |
| SCHEMBL30634105 | 0.84 | EDNRA (0.58) | CCR4PTGES2EDNRA | |
| SCHEMBL21048010 | 0.83 | CCR4 (0.60) | CCR4EDNRA | |
| SCHEMBL20576673 | 0.79 | KDM4E (0.49) | CCR4EDNRA | |
| SCHEMBL20575792 | 0.79 | EDNRA (0.46) | CCR4EDNRA | |
| SCHEMBL30634072 | 0.79 | EDNRA (0.46) | CCR4EDNRA | |
| SCHEMBL22034313 | 0.78 | CCR4 (0.55) | CCR4 | |
| SCHEMBL22034316 | 0.78 | CCR4 (0.55) | CCR4 | |
| SCHEMBL30777785 | 0.77 | AKR1B1 (0.36) | CCR4EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404248-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4201924-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240287004-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| US-11945784-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3891130-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3891130-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4201924-A1 | IRE1 SMALL MOLECULE INHIBITORS | Cornell University (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4201924-A1 | IRE1 SMALL MOLECULE INHIBITORS | Cornell University (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20220024878-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
| EP-3891130-A1 | IRE1 SMALL MOLECULE INHIBITORS | Cornell University (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117634-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117634-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945784-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CCR4 3191/4885PTGES2 2323/4885EDNRA 2093/4885 |
| US-20240287004-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CCR4 3191/4885PTGES2 2323/4885EDNRA 2093/4885 |
| US-20220024878-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CCR4 3191/4885PTGES2 2323/4885EDNRA 2093/4885 |
| US-12404248-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CCR4 3191/4885PTGES2 2323/4885EDNRA 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.